Co-Diagnostics (CODX) Q1 2026 earnings review
A Race Against the Balance Sheet
Co-Diagnostics is successfully executing its clinical pipeline, but the financial runway is alarmingly short. The company completed enrollment for its upper respiratory test (>1,400 patients) and secured critical Indian manufacturing licenses for its PCR Pro instrument. However, the balance sheet tells a dire story: cash plummeted to just $8.2M while operating expenses accelerated to $9.2M for the quarter. With negligible revenue ($0.15M), the company is entirely reliant on capital markets. The surface-level EPS 'improvement' is an illusion driven entirely by massive shareholder dilution.
🐂 Bull Case
The company has crossed a major hurdle by fully enrolling its upper respiratory test study. Filing the FDA 510(k) is the ultimate catalyst to transition from an R&D shop to a commercial enterprise.
The CoSara joint venture in India received a CDSCO license and expanded its territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka, opening a massive $13B addressable market.
🐻 Bear Case
With only $8.2M in the bank and a quarterly operating burn of over $9M, severe dilution or toxic financing is inevitable before meaningful commercial revenues materialize.
Product revenue of $0.15M confirms the legacy business is dead. Everything hinges on unproven new platform approvals in a highly competitive diagnostics market.
⚖️ Verdict: 🔴
Bearish. While clinical and regulatory milestones are progressing, the math on the balance sheet does not work. The company will need to raise substantial capital at highly dilutive valuations just to keep the lights on through the FDA review process.
Key Themes
The EPS 'Improvement' is a Dilution Mirage
Management reported that Net Loss per share 'improved' to -$4.06 from -$7.05 a year ago. This narrative directly contradicts the underlying financials. The actual Net Loss worsened significantly, accelerating from $7.5M to $9.1M. The EPS improvement is mathematically fabricated by a 111% YoY increase in weighted average shares outstanding (from 1.06M to 2.25M), exposing heavy reliance on the ATM facility and brutal shareholder dilution.
Upper Respiratory 510(k) in Sight
The company completed enrollment for the upper respiratory Co-Dx test clinical studies, locking in >1,400 patients. This is a critical milestone resulting from the Q4 decision to drop COVID-19 from the panel (focusing on Flu A/B and RSV) to bypass enrollment bottlenecks. They are now actively preparing the FDA 510(k) submission, setting the stage for their first major US commercial product on the new platform.
Macro Tailwind: Aligning with WHO TB Guidelines
Co-Diagnostics initiated shipments of the PCR Pro instruments and Tuberculosis (TB) test materials to India for clinical performance studies. Crucially, management noted these test kits are specifically designed to support testing approaches reflected in recent World Health Organization (WHO) guidance on TB testing (near point-of-care, tongue swabs). Aligning with global health macro-policy severely de-risks the adoption curve in developing nations.
South Asia Territory Expansion
The CoSara Diagnostics joint venture secured a CDSCO license to manufacture and sell the PCR Pro in India, and immediately signed an agreement expanding its commercial territory. By adding Bangladesh, Pakistan, Nepal, and Sri Lanka, management estimates the regional total addressable market has expanded to approximately $13 billion.
Accelerating Cash Burn
Operating expenses are accelerating, reaching $9.2M (up from $8.6M YoY). R&D spending is understandably high due to clinical studies, but with cash and equivalents down to $8.2M (from $11.9M just three months ago), the company does not have enough runway to survive a standard 120-day FDA review cycle without an immediate capital injection.
Other KPIs
Revenue remains negligible, up slightly from $0.05M YoY but completely detached from the company's $9.2M quarterly operating run rate. The company is effectively a pre-revenue entity until the Co-Dx PCR platform launches.
Losses are accelerating. The Adjusted EBITDA loss worsened from -$7.4M in Q1 2025 to -$8.7M this quarter, driven entirely by the clinical trial scale-up and advancement of international initiatives.
Guidance
Stable. Following the completion of the 1,400-patient enrollment, management confirmed they generated the necessary data and are actively advancing toward a 510(k) filing with the FDA. No specific target date was committed.
Accelerating. The company has officially shipped PCR Pro instruments and test materials to India, signaling the imminent start of in-country clinical performance studies required for regional commercialization.
Key Questions
Cash Runway and Going Concern
With only $8.2 million in cash and a quarterly operating loss exceeding $9 million, exactly how many months of runway does the company have left before requiring a dilutive capital raise?
FDA Submission Timeline
Enrollment for the upper respiratory panel is complete. What is the specific target month for the actual 510(k) submission, and what are the gating items remaining?
CoSara SPAC Status
In previous quarters, management highlighted exploring a SPAC transaction for the CoSara joint venture to unlock capital. What is the current status of this initiative, given the acute need for non-dilutive funding?